Keywords: Bristol-myers Squibb, Erbitux, Metastatic head and neck cancer, USA, FDA

Added indication for Bristol-Myers’ Erbitux approved by FDA

Article | 08 November 2011

Print This

The US Food and Drug Administration yesterday approved US drug major Bristol-Meyers Squibb’s (NYSE: BMY) cancer drug Erbitux ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in